Patent for ColdZyme approved in Japan

The Japanese patent authority has granted Enzymatica’s patent for the cod enzyme that is a key component of Enzymatica’s cold spray ColdZyme® for the Japanese market. The patent is valid until 2036. Corresponding patent was granted by the European Patent Office, EPO, in the spring of 2020.

Enzymatica has developed an improved cod enzyme formulation for ColdZyme, for which new patent applications were globally filed in 2016. The new patent prolongs the protection for ColdZyme and other Enzymatica products based on the same technology platform for another 15 years. This is a major strengthening of the Enzymatica patent portfolio and represents a significant milestone for the continuous commercialization of the company’s key products.

• “Having the new patent also granted in Japan, we will have another large market, besides Europe and Russia, that will provide ColdZyme with a long-term patent protection. Being the sole producer worldwide of the specific deep-water enzyme we also have a technological advantage versus our competitors,” says Claus Egstrand, Chief Operating Officer and Senior Director Growth at Enzymatica.

Besides the granted patent for Japan, Europe and Russia, Enzymatica has filed corresponding applications for other markets, where the patent is currently being reviewed.

Enzymatica’s patent portfolio is managed by leading European IP firm Potter Clarkson.

For more information, please contact:

Claus Egstrand, Chief Operating Officer & Senior Director Growth, Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: claus.egstrand@enzymatica.com

Bengt Baron, Executive Chairman, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: bengt.baron@outlook.com

Carl-Johan Wachtmeister, Communication manager, Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: carl-johan.wachtmeister@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily

conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica’s certified adviser is Erik Penser Bank. Tel: +46 (0)8 463 83 00 E-mail: certifiedadviser@penser.se